Jim Cramer Highlights Eli Lilly's Drug Potential Beyond Diabetes and Obesity

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer put under the microscope. Cramer highlighted the importance of the company’s GLP-1 drug, as he stated:

“I suggest, for example, that you consider Eli Lilly because of its remarkable GLP-1 diabetes and weight loss drug. Those are the most obvious uses. But when this year is over, I gotta tell you something, I think it could be used for everything from the silent killer of hypertension to dementia, and yes, alcoholism. Lilly’s stock has been stalled because of the drug’s clumsy delivery mechanism.

It’s an injectable that needs to be refrigerated. Not ideal, but Lilly’s testing a one-a-day pill… that could alleviate the principal objections to the life-saving weight loss drug. It will expand the market in a huge way. Unfortunately, both the injectable and apparently the pill take off all body weight, not just fat. Still, a successful pill could take Lilly’s market cap from $781 billion, where it is now, into the trillion-dollar winner circle. That makes it worth buying even up here.”

Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, obesity, oncology, immunology, neuroscience, and gastrointestinal conditions.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.